Financing led by institutional investors, with participation from new investor Eli Lilly and Company Inclusive of this investment, a total of $123 million in equity financing received from ...
-- Bruton’s tyrosine kinase (BTK) SH2 inhibitor reduced skin inflammation in a clinically-relevant model of chronic spontaneous urticaria (CSU) ...
A proprietary Src homology 2 (SH2) platform of integrated technologies was applied for the discovery of REX-7117 and REX-5376, two highly potent, selective and orally available SH2 domain-targeting ...
The MarketWatch News Department was not involved in the creation of this content. -- Financing led by institutional investors, with participation from new investor Eli Lilly and Company -- Inclusive ...
SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results